February 27, 2024

Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

February 22, 2024

Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

November 07, 2023

Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates

August 01, 2023

Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates

June 28, 2023

Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market

May 15, 2023

Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates

May 10, 2023

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

May 08, 2023

Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023

May 01, 2023

Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

March 08, 2023

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

March 01, 2023

Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023

December 28, 2022

Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

November 09, 2022

Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates

November 02, 2022

Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022

October 17, 2022

Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

September 09, 2022

Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market

August 22, 2022

Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

August 09, 2022

Minerva Neurosciences Reports Second Quarter 2022 Financial Results and Business Updates

May 04, 2022

Minerva Neurosciences Reports First Quarter 2022 Financial Results and Business Updates

April 07, 2022

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of a New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

March 01, 2022

Minerva Neurosciences Reports Fourth Quarter 2021 Financial Results and Business Updates

February 28, 2022

Minerva Neurosciences Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

November 08, 2021

Minerva Neurosciences Reports Third Quarter 2021 Financial Results and Business Updates

November 03, 2021

Minerva Neurosciences Announces FDA Recommendation for Type C Meeting to Discuss Evidence for Use of Roluperidone as Monotherapy for the Treatment of Negative Symptoms in Patients with Schizophrenia in Advance of Potential NDA Submission

November 01, 2021

Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8

October 11, 2021

Minerva Neurosciences Announces Promotion of Geoff Race to President

September 30, 2021

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia

September 08, 2021

Minerva Neurosciences Announces Appointment of Dr. Ramana Kuchibhatla as Senior Vice President and Head of Research & Development

August 02, 2021

Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates

July 26, 2021

Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021

June 10, 2021

Minerva Neurosciences to Present at JMP Securities Life Sciences Conference

May 28, 2021

Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference

May 12, 2021

Minerva Neurosciences Reports First Quarter 2021 Financial Results and Business Updates

May 11, 2021

Minerva Neurosciences Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

May 05, 2021

Minerva Neurosciences to Report First Quarter 2021 Financial Results and Business Updates on May 12, 2021

March 08, 2021

Minerva Neurosciences Reports Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates

March 01, 2021

Minerva Neurosciences to Report Fiscal 2020 Fourth Quarter and Year End Financial Results and Business Updates on March 8, 2021

January 19, 2021

Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million

January 06, 2021

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Minerva Neurosciences, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

December 01, 2020

Minerva Neurosciences Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Roluperidone

November 09, 2020

Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference

November 02, 2020

Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates

October 26, 2020

Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020

September 09, 2020

Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference

September 02, 2020

Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference

August 13, 2020

Minerva Neurosciences to Present at JMP Securities CNS Forum

August 03, 2020

Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates

July 27, 2020

Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020

July 01, 2020

Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)

June 01, 2020

REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia